Bioventus’ Post

Orthocell Ltd (ASX:OCC, OTC:ORHHF) has taken another step toward fulfilling its global market expansion ambitions, officially entering the Canadian #biotech market with the first sale of its products through distribution partner BioHorizons. This first sale of #Striate+, for use in dental guided bone and #TissueRegeneration, follows regulatory approval from Health Canada in early July and demonstrates the rapid conversion potential of OCC products from approval, to sales, to revenue generation. The company estimates the Canadian regenerative medicine market to be worth A$60 million, with a global market opportunity of more than A$1 billion for its Striate product. “Commencement of sales in Canada is further validation of Orthocell’s expanding global footprint,” Orthocell managing director Paul Anderson said. More at #Proactive #Biotech #Biopharmaceutcials #RegenerativeMedicine http://ow.ly/4P7g105HPMk

Scared of getting surgery for a joint replacement? No worries, with the help of regenerative biologics, we can reverse the inflammatory process, improve cartilage production, and avoid the need for surgery! Hit link in bio to book your consultation with @recellebrate Disclaimer: The content of this post, including information on supplements, medicines, or methods, is for informational purposes only and is not intended as medical advice. Consult a healthcare professional before starting any new supplement regimen. #jointreplacement #nosurgeryjointreplacemenet #cartilageproduction #viralreels

Three posters presented at the ASHP Midyear Clinical Meeting delved deeper into perioperative #painmanagement. https://lnkd.in/eEXciDm8 #Pharmacy #PharmacyEducation Drug Topics

The final step in the platelet-rich plasma (PRP) journey is to gently agitate the collection tube so that the platelets are thoroughly resuspended into the patient’s plasma. Once collected with a syringe, the physician injects or applies the PRP to the target area. The patient’s own platelets then release growth factors at the site of the injury and begin the healing cascade. To follow the full PRP journey, stay tuned to this channel to see more advancements in orthobiologics: https://lnkd.in/gu_R4Jyf #prp #prptherapy #prptreatment #tropocells #sportsmedicine #orthopedics #healing #biologics #orthobiologics #transcend #recovery

Cecelia Koetting, OD FAAO DipABO, (University of Colorado Anschutz Medical Campus) and Mile Brujic, OD, (PREMIER VISION GROUP) discuss how 2 new pharmaceutical treatments have the potential to change the paradigm for treating #DryEyeDisease. #MeibomianGlandDysfunction (MGD) has a number of causes, but only a single result: #OcularSurface dryness. In fact, most instances of dry eye disease (DED) (approximately 85%) have some evaporative component, often instigated by a dysfunction of the meibomian glands.1 Research shows that patients with MGD usually (approximately 85% of the time) have a preponderance of #Demodex mites, which leave cylindrical waste materials along the lash follicle, clogging the meibomian gland and, ultimately leading to Demodex blepharitis.2,3 Read more: https://brnw.ch/21wJdVg #MeibomianGland #MGD #OcularSurfaceDryness #DryEye #DryEyeSymptoms #EyeHealth #EyeCare #DED #Optometry #Optometrist

PRP (Platelet Rich Plasma) injections are used to treat pain relief by using a machine to separate the platelet-rich plasma from the rest of your blood. One of the biggest benefits continues to be that it’s a non-operative, minimally invasive treatment option with clinical studies supporting its use for multiple conditions. Learn more about PRP injections here: https://bit.ly/3MqUHZb. #SportsMedicine #Orthobiologics #PRP #PlateletRichPlasma

The secret is out about Lacrifill, an #FDA-cleared #dryeyedisease therapy. So, who better to celebrate with than Darrell White, MD? Read Dr. White's thoughts about Lacrifill, which will be marketed by Nordic Pharma, in his latest Healio blog post. Find out why he's excited for this promising treatment and what benefits it may offer patients and #ophthalmologists. 🔗 below: #OcularSurgeryNews #Cornea #Eyedrops https://lnkd.in/ekBP-HS2

The golden standard treatment for #obesity and type 2 #diabetes, gastric bypass surgery, leads to higher rates of diabetes remission and improvement yet comes with high invasion risks to the patients.  🚀 AltrixBio Inc. is inspired to develop an oral daily therapy that would mimic the benefits of surgery without the risks. 💊 The lead asset, #LuCI #AJN003, is a new formulation of a safe marketed drug, #Sucralfate. The new formulation allows LuCI to bind healthy intestinal mucosa independent of the pH. It thus forms a luminal barrier that prevents food contact with proximal intestinal mucosa, creating a temporary coating that replicates the effect of gastric bypass. 📖 Learn more here 👉 https://lnkd.in/ec5bqgP6 #type2 #diabetes #obesity #Gastricbypasssurgery #medication #pharma #biotech #drug #innovation #science #technology #investment #partnerships #Bioneex

Market Scope estimates that nearly 2,000 vitrectomy machines were sold globally in 2023. Looking forward, however, the percentage of United States retinal surgeons planning to purchase a new vitrectomy machine in the next 12 months continues to fall, down to only 2 percent in 2023 from a high of 6 percent in 2020. The main growth drivers for vitrectomy machines are typically technology upgrades, surgery center expansion, market penetration, and replacements. However, it’s possible a recent acquisition could prove to be a driver on its own. ZEISS Medical Technology’s December acquisition of DORC Dutch Ophthalmic Research Center (International) combines the strong reputation of the Eva vitrectomy machine with Zeiss’ status as a global market leader with extensive financial resources and established sales networks—all while filling the biggest void in Zeiss’ product line. Will this acquisition convince more surgeons it’s time to purchase a new machine? We will be closely monitoring this and much more in our Ophthalmic Market Trends—Quarterly US Retina Edition.      These concise, unbiased expert-reviewed, survey-based editions are published every quarter to drive innovation and uncover competitive intelligence. Coverage includes vitrectomy volume and locations, vitrectomy machine use and market share, reusable and disposable instruments, visualization agents, IVT injections by disease and product, DME treatments, corticosteroid use, and photocoagulation volume and usage. Please visit https://bit.ly/Q223OMT4 to learn more about these trends and subscribe, or email matthew@market-scope.com to request a sample. #Vitrectomy #Machine #RetinalSurgery #PurchasePlans #MarketDrivers #Ophthalmology #Ophthalmic

The #dermal #fillers offer a non-surgical alternative to procedures like facelifts, addressing concerns such as wrinkles, volume loss, and sagging skin. Increasing #demand for Non-Surgical #cosmetic Procedures more people are opting for #minimally invasive aesthetic #treatments 𝐕𝐢𝐞𝐰 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/gWqxWCGp Galderma, Sinclair Pharma Korea, Allergan, Merz Pharma Dessau, Merz Pharma GmbH & Co KGaA Reinheim, Suneva Medical, TEOXANE Laboratories, Prollenium Medical Technologies Inc., Laboratoires Vivacy, Fidia Pharma #marketanalysis #marketgrowth #marketdata #marketsize #marketshare #markettrends #marketreport #marketoutlook #marketoverview #drivers #marketresearchreport #marketsegmentation #marketsummary #restraints #researchanddevelopment #researchmethods #researchreport #marketdemand